November 6, 2019

AUROBINDO

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir,

Sub : Clarification on news article "Aurobindo Pharma under USFDA scrutiny" – Reg.,
Ref : E-mails dated November 5, 2019 received from BSE & NSE

With reference to your email dated 5th November 2019 seeking clarification on news article appearing on economictimes.indiatimes.com dated 5th November 2019, captioned "Aurobindo Pharma under USFDA scrutiny", we inform the following:

The United States Food and Drug Administration (US FDA) inspected Unit V, API manufacturing facility at Pashamylaram, Hyderabad and Unit VIII, API manufacturing facility at Gaddapotharam, Hyderabad of the Company from 21st to 28th October 2019 and from 21st to 25th October 2019, respectively. At the end of the inspections, we have been issued a 'Form 483' with 4 observations for each facility.

We believe that these observations are related to procedural improvements and none of the observations are related to data integrity. The Company will be responding to USFDA as per the prescribed time lines.

With respect to Unit IV, formulation manufacturing facility at Pashamylaram, Hyderabad, the inspection is in progress.

We further inform you that USFDA audit is an activity under the normal course of business in the pharmaceutical industry. The Company regularly informs all material events and currently we do not have any information which is material to the Company's operations. We will continue to intimate stock exchanges if there is any material development.

Please take the above information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LTD. * HYD. *